Natera, Inc. (NASDAQ:NTRA) Q3 2024 Earnings Conference Call November 12, 2024 4:30 AM ET

Company Participants

Mike Brophy - CFO
Steve Chapman - CEO
Alexey Aleshin - GM Oncology, CMO

Conference Call Participants

Puneet Souda - Leerink Partners
Daniel Brennan - TD Cowen
Tejas Savant - Morgan Stanley
Rachel Vatnsdal - JP Morgan
Douglas Schenkel - Wolfe Research
Matthew Sykes - Goldman Sachs
Tycho Peterson - Jefferies

Operator

Welcome to Natera's 2024 Third Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode. Following management's prepared remarks, we will hold a Q&A session. [Operator Instructions] As a reminder, this conference call is being recorded today, November 12, 2024.

I would now like to turn the conference call over to Michael Brophy, Chief Financial Officer. Please go ahead.

Mike Brophy

Thanks Operator Good afternoon. Thank you for joining our conference call to discuss the results of our third quarter of 2024. On the line I am joined by Steve Chapman, our CEO, and Alexey Aleshin, General Manager of Oncology and Chief Medical Officer. Solomon Moshkevich, President, Clinical Diagnostics, couldn't be here today, but will be joining us again next quarter.

Today's conference call is being broadcast live via webcast. We will be referring to a slide presentation that has been posted to investor.natera.com. A replay of the call will also be posted to our IR site as soon as it's available.

Starting on slide two, during the course of this conference call we will make forward-looking statements regarding future events and our anticipated future performance, such as our operational and financial outlook and projections, our assumptions for that outlook, market size, partnerships, clinical studies and expected results, opportunities and strategies and expectations for various current and future products including product capabilities, expected release dates, reimbursement coverage and related effects on our financial and operating results.

We caution you that such statements reflect our best judgment based on factors currently known to us and that actual events or results could differ materially. Please refer to the documents we file from time to time with the SEC, including our most recent Form-10K or 10-Q and the Form-8K filed with today's press release.

Those documents identify important risks and other factors that may cause our actual results to differ materially from those contained in or suggested by forward-looking statements. Forward-looking statements made during the call are being made as of today, November 12, 2024. If this call is replayed or reviewed after today, the information presented during the call may not contain current or accurate information.